News
Almirall + Mercachem = Looking for new cytokine blockers
Published on 03/05/2017
Almirall S.A. and Mercachem have entered into an exclusive discovery collaboration focusing on the development of oral cytokine blockers for the treatment of inflammatory skin diseases.
Almirall + Nuevolution = Fighting together inflammatory skin diseases
Published on 20/03/2017
Almirall S.A. and Nuevolution A/S have entered into a global strategic collaboration focusing on the development and commercialization of Nuevolution's novel RORγt inverse agonist (inhibitor) program for treatment of inflammatory...
Subscribe to our latest news
This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our policy of cookies, click on the link for more information.
ACEPTARYou are leaving AlmirallShare
You are now leaving AlmirallShare and being redirected to the Innocentive website which is maintained by a third party. We do not have any control on the contents, privacy policy or security measures implemented therein. As they may differ from ours, please do read Innocentive website’s privacy policy carefully. Click “Accept” to proceed or “Cancel” to remain on AlmirallShare
If you are already a user of our innovation community, click the Login button to submit your idea.
LoginIf you are not a registered user yet, click the Register your account button.
Register accountYou will leave an Almirall website
You are about to leave an Almirall website and you will access another website where our privacy is not applied. Almirall is not reponsible for the content of that external website.
You are leaving AlmirallShare
You are now leaving AlmirallShare and being redirected to the InnoCentive website which is maintained by a third party. Privacy policy and security measures implemented therein may differ from ours.